GeneMatrix Inc.

Korea Bio Park B Bldg. 8F 700 Daewangpangyo-ro, Bundang-gu, 13488 Seongnam-si
Korea, Republic
Telephone +82 31 628 2000
Fax +82 31 628 2001
info@genematrix.net

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests
  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.01  DNA testing

DNA testing

  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)

Polymerase chain reaction (PCR)

Our products

Product category: Diagnostic rapid tests

HepB Typer-Lamivudine

Chronic hepatitis B can progress to cirrhosis and hepatocellular carcinoma, and the inhibition of the proliferation of the causative hepatitis B virus is clinically important. As the duration of antiviral administration increases, the risk of drug resistance also increases, making long-term inhibition of hepatitis B viral load more difficult.
HepB Typer-Lamivudine provides a sensitive diagnosis of mutations that cause Lamivudine resistance and provides guidelines for the drug regimen of chronic hepatitis B treatment.

Features
  • High Accuracy and Sensitivity
  • - Analytical sensitivity: 100 IU/ml
  • - Fully concordant with direct or clonal sequencings
  • Early Detection of Drug Resistant Virus
  • - Detects drug resistant virus of less than 10% of the whole viral population
  • Monitoring of Relative Abundance
  • - Predicts viral breakthrough, the main cause for failure in hepatitis B treatment, by monitoring predominance of resistant virus known to precede viral breakthrough
  • Definitive Determination of Mixture of Multiple Mutations
  • - Precisely identifies mixture of multiple mutations, whereas direct sequencing could not identify specific genotypes with a double mutation in one codon due to the inability of sequencing to determine haplotype

More Less

Product category: Diagnostic rapid tests

HepB Typer-Adefovir

Chronic hepatitis B can progress to cirrhosis and hepatocellular carcinoma, and the inhibition of the proliferation of the causative hepatitis B virus is clinically important. As the duration of antiviral administration increases, the risk of drug resistance also increases, making long-term inhibition of hepatitis B viral load more difficult.
HepB Typer-Adefovir provides a sensitive diagnosis of mutations that cause Adefovir resistance and provides guidelines for the drug regimen of chronic hepatitis B treatment.

Features
  • High Accuracy and Sensitivity
  • - Analytical sensitivity: 100 IU/ml
  • - Fully concordant with direct or clonal sequencings
  • Early Detection of Drug Resistant Virus
  • - Detects drug resistant virus of less than 10% of the whole viral population
  • Monitoring of Relative Abundance
  • - Predicts viral breakthrough, the main cause for failure in hepatitis B treatment, by monitoring predominance of resistant virus known to precede viral breakthrough
  • Definitive Determination of Mixture of Multiple Mutations
  • - Precisely identifies mixture of multiple mutations, whereas direct sequencing could not identify specific genotypes with a double mutation in one codon due to the inability of sequencing to determine haplotype

More Less

Product category: Diagnostic rapid tests

HepC Typer

The HCV genotype is a key predictor of antiviral response and should be reviewed prior to antiviral therapy, providing important information in determining the treatment duration and dosage.
Because HCV has a variety of genotypes and subtypes and mixed HCV infection scan be present in some patients, accurate genotype and subtype diagnosis is important.
HepC Typer provides guidelines for the antiviral drug regimen, dosage, and duration, and enables monitoring of mixed infections with the HCV genotype test.

Features
  • High accuracy and sensitivity: analytical sensitivity: 100 IU / ml
  • 6 genotypes and 31 subtypes can be distinguished.
  • Monitoring mixed infections by a multiple geneotypes
  • Insurance number:Na 596-2 / Insurance code: C6092
  • High accuracy and sensitivity
  • - Analytical sensitivity: 100 IU / ml
  • - Higher accuracy compared to sequencing or hybridization methods
  • High Resolution Genotyping of 6 Genotypes and Subtypes
  • - Determines not only 6 genotypes but also 31 subtypes
  • Effective Detection of Mixed Genotype Infections
  • - Monitoring on mixed infection is significantly important for HCV to which the gene mutation progress quite rapidly
  • User Friendly Analysis
  • - Supporting fully automated data acquisition and high-throughput analysis (96 samples)

More Less

Product category: DNA testing

TheraTyper - GJB2

TheraTyper-GJB2 is a test to diagnose gene mutations that cause abnormalities of GJB2 (connexin26), a protein that constitutes the intercellular channel of the inner ear (cochlea). It enables prenatal prediction andnewborn screening of hearing loss.
TheraTyper-GJB2 helps early detection of hearing loss at birth to maximize efficient treatment and rehabilitation.

Features
  • Higher Accuracy and Reproducibility
  • - Higher accuracy compared to the conventional RFLP or sequencing methods
  • Diagnosis of 3 Most Frequent Loss Mutations in Congenital Hearing Loss
  • - 35delG, 167delT and 235delC
  • Providing Active Treatment Opportunities via Effective Screening

More Less

About us

Company details

CEO Message

Medical and bio-technology is the key field that can lead and shape the 4th industrial revolution, including smart healthcare, new drug, and medical devices.

Genematrix has focused its R&D on convergence technology, which consistently grows and has influence in the world market, and made every effort on commercialization since it has been listed on the KOSDAQ as a technology innovation corporation in 2009. Genematrix has developed core platform technologies in molecular diagnostics that differentiated itself from existing technologies, realizing that the personalized medicine is the future of the medical and biotech industries. Genematrix is also making efforts to develop new natural pharmaceutical materials and new drugs for disease treatment.

Genematrix does not only intend to maximize shareholder value by constantly creating growth momentum through partnering in the global market, but also to fulfill the company's role in the people-oriented 4th industry by taking a social responsibility in such field promoting national health and creating new jobs.

More Less